All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cancer location (esophagus) cancer location (gastric) cancer location (gastro-esophageal) cancer type (metastatic) ECOG 0 ECOG 1 Gender, female Gender, male metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (CPS >1) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced mGC or mGEJC, anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ATTRACTION-2 (Kang), 2017 0.63 [0.51; 0.78]
CheckMate 649, 2021 0.80 [0.68; 0.94]
CheckMate 649 (PDL1 CPS>5), 2021 0.71 [0.59; 0.86]
JAVELIN Gastric 100, 2020 0.91 [0.74; 1.11]
JAVELIN Gastric 100 (PDL1>1%), 2020 1.13 [0.57; 2.24]
JAVELIN Gastric 300, 2018 1.10 [0.88; 1.37]
KEYNOTE-061 (all population), 2018 0.94 [0.79; 1.12]
KEYNOTE-061 (PDL1 CPS>1), 2018 0.82 [0.66; 1.02]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.91 [0.75; 1.11]
KEYNOTE-062 (P vs C ; CPS>10), 2020 0.69 [0.49; 0.97]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.85 [0.70; 1.03]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 0.85 [0.62; 1.17]
0.84 [0.77 ; 0.92 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, CheckMate 649 (PDL1 CPS>5), 2021, JAVELIN Gastric 100, 2020, JAVELIN Gastric 100 (PDL1>1%), 2020, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018, KEYNOTE-061 (PDL1 CPS>1), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 12 48% 6,324 moderate low deaths (OS) (extension)detailed results ATTRACTION-2 (Kang), 2017 0.62 [0.51; 0.76]
0.62 [0.51 ; 0.76 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable PFS (extension)detailed results ATTRACTION-2 (Kang), 2017 0.60 [0.48; 0.74]
0.60 [0.48 ; 0.74 ] ATTRACTION-2 (Kang), 2017 1 0% 493 NA not evaluable progression or deaths (PFS)detailed results ATTRACTION-2 (Kang), 2017 0.60 [0.48; 0.74]
CheckMate 649, 2021 0.77 [0.68; 0.87]
CheckMate 649 (PDL1 CPS>5), 2021 0.68 [0.57; 0.82]
JAVELIN Gastric 100, 2020 1.04 [0.85; 1.28]
JAVELIN Gastric 100 (PDL1>1%), 2020 1.04 [0.53; 2.03]
JAVELIN Gastric 300, 2018 1.73 [1.38; 2.17]
KEYNOTE-061 (all population), 2018 1.49 [1.25; 1.77]
KEYNOTE-061 (PDL1 CPS>1), 2018 1.27 [1.03; 1.57]
KEYNOTE-062 (P vs C ; CPS>1), 2020 1.66 [1.37; 2.01]
KEYNOTE-062 (P vs C ; CPS>10), 2020 1.10 [0.80; 1.52]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.84 [0.70; 1.01]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 0.73 [0.53; 1.00]
1.02 [0.82 ; 1.26 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, CheckMate 649 (PDL1 CPS>5), 2021, JAVELIN Gastric 100, 2020, JAVELIN Gastric 100 (PDL1>1%), 2020, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018, KEYNOTE-061 (PDL1 CPS>1), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 12 92% 6,324 moderate low DCRdetailed results ATTRACTION-2 (Kang), 2017 1.99 [1.24; 3.18]
JAVELIN Gastric 100, 2020 0.62 [0.43; 0.89]
JAVELIN Gastric 300, 2018 0.37 [0.23; 0.60]
0.77 [0.31 ; 1.90 ] ATTRACTION-2 (Kang), 2017, JAVELIN Gastric 100, 2020, JAVELIN Gastric 300, 2018 3 92% 1,363 moderate not evaluable objective responses (ORR)detailed results ATTRACTION-2 (Kang), 2017 34.90 [2.12; 573.88]
CheckMate 649, 2021 1.63 [1.30; 2.04]
CheckMate 649 (PDL1 CPS>5), 2021 1.80 [1.35; 2.39]
JAVELIN Gastric 100, 2020 0.91 [0.55; 1.51]
JAVELIN Gastric 300, 2018 0.49 [0.15; 1.66]
KEYNOTE-061 (all population), 2018 0.88 [0.53; 1.45]
KEYNOTE-061 (PDL1 CPS>1), 2018 1.20 [0.68; 2.09]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.29 [0.19; 0.45]
KEYNOTE-062 (P vs C ; CPS>10), 2020 0.55 [0.29; 1.04]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.60 [1.12; 2.28]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 1.82 [1.02; 3.26]
1.06 [0.72 ; 1.58 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, CheckMate 649 (PDL1 CPS>5), 2021, JAVELIN Gastric 100, 2020, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018, KEYNOTE-061 (PDL1 CPS>1), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 11 87% 5,715 moderate low AE (any grade)detailed results ATTRACTION-2 (Kang), 2017 1.93 [1.10; 3.38]
JAVELIN Gastric 100, 2020 1.25 [0.67; 2.33]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.34 [0.11; 1.06]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.68 [0.19; 2.43]
1.01 [0.51 ; 2.00 ] ATTRACTION-2 (Kang), 2017, JAVELIN Gastric 100, 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 4 63% 1,964 moderate not evaluable AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.10 [0.75; 1.62]
JAVELIN Gastric 100, 2020 0.98 [0.68; 1.40]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.09 [0.06; 0.14]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.16 [0.79; 1.71]
0.58 [0.18 ; 1.81 ] ATTRACTION-2 (Kang), 2017, JAVELIN Gastric 100, 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 4 97% 1,964 low not evaluable AE leading to death (grade 5)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.37; 1.12]
JAVELIN Gastric 100, 2020 1.22 [0.57; 2.59]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.19; 4.80]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.64 [0.39; 6.94]
0.86 [0.57 ; 1.30 ] ATTRACTION-2 (Kang), 2017, JAVELIN Gastric 100, 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 4 0% 1,964 low not evaluable AE leading to treatment discontinuation (any grade)detailed results ATTRACTION-2 (Kang), 2017 0.93 [0.45; 1.92]
JAVELIN Gastric 100, 2020 0.43 [0.28; 0.64]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.19 [0.09; 0.38]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.73 [1.13; 2.66]
0.61 [0.24 ; 1.56 ] ATTRACTION-2 (Kang), 2017, JAVELIN Gastric 100, 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 4 92% 1,964 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.69 [0.29; 1.66]
0.69 [0.29 ; 1.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable SAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 0.75 [0.52; 1.10]
JAVELIN Gastric 100, 2020 1.26 [0.86; 1.83]
0.97 [0.59 ; 1.60 ] ATTRACTION-2 (Kang), 2017, JAVELIN Gastric 100, 2020 2 71% 972 moderate not evaluable SAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.92 [0.61; 1.40]
0.92 [0.61 ; 1.40 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable STRAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 2.13 [0.96; 4.71]
CheckMate 649, 2021 1.98 [1.50; 2.61]
JAVELIN Gastric 100, 2020 0.79 [0.42; 1.50]
1.52 [0.84 ; 2.76 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, JAVELIN Gastric 100, 2020 3 71% 2,521 moderate not evaluable STRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.67 [0.90; 7.91]
CheckMate 649, 2021 1.80 [1.33; 2.44]
1.85 [1.39 ; 2.48 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 0% 2,040 moderate not evaluable TRAE (any grade)detailed results ATTRACTION-2 (Kang), 2017 2.05 [1.36; 3.09]
CheckMate 649, 2021 2.17 [1.49; 3.17]
JAVELIN Gastric 100, 2020 0.47 [0.31; 0.69]
JAVELIN Gastric 300, 2018 0.34 [0.22; 0.52]
KEYNOTE-061 (all population), 2018 0.21 [0.14; 0.31]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.11 [0.06; 0.18]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.40 [0.70; 2.80]
0.58 [0.24 ; 1.38 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, JAVELIN Gastric 100, 2020, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 7 96% 4,444 moderate not evaluable TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.53 [1.09; 5.83]
CheckMate 649, 2021 1.80 [1.47; 2.21]
JAVELIN Gastric 100, 2020 0.31 [0.19; 0.49]
JAVELIN Gastric 300, 2018 0.22 [0.12; 0.40]
KEYNOTE-061 (all population), 2018 0.31 [0.21; 0.47]
0.62 [0.22 ; 1.75 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, JAVELIN Gastric 100, 2020, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 5 97% 3,452 moderate not evaluable TRAE leading to death (grade 5)detailed results ATTRACTION-2 (Kang), 2017 1.22 [0.23; 6.37]
CheckMate 649, 2021 7.88 [0.42; 149.34]
JAVELIN Gastric 100, 2020 0.49 [0.02; 14.64]
JAVELIN Gastric 300, 2018 0.48 [0.02; 14.39]
KEYNOTE-061 (all population), 2018 2.84 [0.29; 27.42]
1.58 [0.53 ; 4.68 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, JAVELIN Gastric 100, 2020, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 5 0% 3,452 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results ATTRACTION-2 (Kang), 2017 1.10 [0.33; 3.63]
CheckMate 649, 2021 1.85 [1.48; 2.30]
JAVELIN Gastric 100, 2020 0.31 [0.18; 0.50]
JAVELIN Gastric 300, 2018 0.74 [0.27; 2.03]
KEYNOTE-061 (all population), 2018 0.55 [0.24; 1.28]
0.76 [0.30 ; 1.93 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, JAVELIN Gastric 100, 2020, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 5 91% 3,452 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.14; 2.92]
CheckMate 649, 2021 2.12 [1.55; 2.90]
1.49 [0.51 ; 4.32 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021 2 56% 2,040 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.96 [0.02; 48.74]
KEYNOTE-061 (all population), 2018 0.16 [0.01; 3.11]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.50 [0.08 ; 3.03 ] JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 4 0% 1,923 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 649, 2021 2.27 [1.34; 3.84]
JAVELIN Gastric 300, 2018 0.04 [0.00; 0.71]
KEYNOTE-061 (all population), 2018 0.54 [0.21; 1.38]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.10 [0.03; 0.27]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.81 [0.48; 1.37]
0.46 [0.15 ; 1.40 ] CheckMate 649, 2021, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 5 89% 3,472 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 649, 2021 0.68 [0.26; 1.81]
JAVELIN Gastric 300, 2018 0.19 [0.02; 1.63]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.09 [0.01; 0.73]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.87 [0.35; 2.19]
0.48 [0.20 ; 1.14 ] CheckMate 649, 2021, JAVELIN Gastric 300, 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 4 40% 2,902 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.06; 15.44]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.49 [0.02; 14.58]
0.73 [0.09 ; 6.29 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Colitis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
KEYNOTE-061 (all population), 2018 0.16 [0.01; 3.11]
0.35 [0.04 ; 3.29 ] ATTRACTION-2 (Kang), 2017, KEYNOTE-061 (all population), 2018 2 0% 1,061 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.22; 17.71]
CheckMate 649, 2021 1.06 [0.49; 2.26]
JAVELIN Gastric 300, 2018 0.12 [0.01; 2.25]
KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.16 [0.05; 0.55]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.61 [0.28; 1.34]
0.61 [0.28 ; 1.37 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 6 50% 3,963 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
0.94 [0.02 ; 47.47 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
CheckMate 649, 2021 1.45 [0.85; 2.46]
JAVELIN Gastric 300, 2018 0.16 [0.02; 1.31]
KEYNOTE-061 (all population), 2018 0.94 [0.06; 15.08]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.20 [0.06; 0.69]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.83 [0.38; 1.83]
0.67 [0.30 ; 1.49 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 6 57% 3,963 moderate not evaluable Dizziness TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.06; 15.69]
0.73 [0.09 ; 6.31 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 low not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 9.86 [0.54; 180.88]
9.86 [0.54 ; 180.88 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Fatigue TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.48 [0.07; 3.47]
CheckMate 649, 2021 1.76 [0.96; 3.22]
JAVELIN Gastric 300, 2018 0.48 [0.04; 5.32]
KEYNOTE-061 (all population), 2018 0.49 [0.19; 1.26]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.06 [0.01; 0.50]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.35 [0.66; 2.76]
0.72 [0.33 ; 1.56 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 6 64% 3,963 moderate serious Febrile neutropenia TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.08 [0.00; 1.40]
0.08 [0.00 ; 1.40 ] JAVELIN Gastric 300, 2018 1 0% 361 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 1.73 [1.04; 2.86]
1.73 [1.04 ; 2.86 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 7.60 [0.40; 144.43]
7.60 [0.40 ; 144.43 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 1.81 [0.97; 3.36]
1.81 [0.97 ; 3.36 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
0.68 [0.04 ; 10.84 ] ATTRACTION-2 (Kang), 2017, KEYNOTE-061 (all population), 2018 2 0% 1,061 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
3.77 [0.17 ; 84.06 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
KEYNOTE-061 (all population), 2018 23.34 [3.13; 174.05]
KEYNOTE-062 (P vs C ; CPS>1), 2020 1.92 [0.06; 57.64]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.07; 58.57]
4.31 [0.72 ; 25.71 ] ATTRACTION-2 (Kang), 2017, KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 4 28% 2,053 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
CheckMate 649, 2021 2.38 [0.83; 6.77]
JAVELIN Gastric 300, 2018 1.29 [0.28; 5.84]
1.95 [0.85 ; 4.47 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, JAVELIN Gastric 300, 2018 3 0% 2,401 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
CheckMate 649, 2021 1.18 [0.36; 3.88]
JAVELIN Gastric 300, 2018 0.72 [0.16; 3.25]
0.97 [0.40 ; 2.40 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, JAVELIN Gastric 300, 2018 3 0% 2,401 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 649, 2021 2.87 [1.61; 5.12]
JAVELIN Gastric 300, 2018 0.48 [0.04; 5.32]
1.74 [0.36 ; 8.39 ] CheckMate 649, 2021, JAVELIN Gastric 300, 2018 2 50% 1,910 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 1.93 [0.06; 57.86]
KEYNOTE-061 (all population), 2018 0.47 [0.02; 14.02]
0.95 [0.09 ; 10.52 ] JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018 2 0% 931 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 5.98 [0.71; 50.01]
2.43 [0.23 ; 25.98 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 34% 992 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.03 [0.00; 0.51]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.70 [0.32; 1.56]
0.20 [0.01 ; 4.07 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 77% 992 low not evaluable Nausea TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
CheckMate 649, 2021 1.03 [0.55; 1.95]
JAVELIN Gastric 300, 2018 0.24 [0.01; 5.32]
KEYNOTE-061 (all population), 2018 0.47 [0.04; 5.19]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.05 [0.01; 0.37]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.03 [0.53; 2.02]
0.61 [0.28 ; 1.34 ] ATTRACTION-2 (Kang), 2017, CheckMate 649, 2021, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 6 46% 3,963 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.29 [0.96; 1.72]
JAVELIN Gastric 300, 2018 0.02 [0.00; 0.30]
KEYNOTE-061 (all population), 2018 0.02 [0.00; 0.25]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.01 [0.00; 0.08]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.87 [0.58; 1.30]
0.25 [0.08 ; 0.74 ] CheckMate 649, 2021, JAVELIN Gastric 300, 2018, KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 5 88% 3,472 moderate serious Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.81 [0.67; 4.92]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.06 [0.00; 1.02]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.49 [0.60; 3.70]
1.04 [0.32 ; 3.44 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 60% 2,541 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.47 [0.02; 14.02]
0.47 [0.02 ; 14.02 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.40 [0.80; 2.44]
KEYNOTE-061 (all population), 2018 0.08 [0.00; 1.38]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.97 [0.36; 10.84]
1.13 [0.44 ; 2.87 ] CheckMate 649, 2021, KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 4 25% 3,111 moderate not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.12 [0.54; 2.32]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 5.91 [0.29; 118.71]
1.33 [0.50 ; 3.53 ] CheckMate 649, 2021, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 10% 2,043 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
2.04 [0.21 ; 20.20 ] ATTRACTION-2 (Kang), 2017, KEYNOTE-061 (all population), 2018 2 0% 1,061 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.77 [0.08 ; 7.42 ] ATTRACTION-2 (Kang), 2017, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 0% 1,483 low not evaluable Pyrexia TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Rash TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.07; 58.57]
1.04 [0.12 ; 8.94 ] ATTRACTION-2 (Kang), 2017, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 0% 1,483 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 5.92 [0.71; 49.31]
5.92 [0.71 ; 49.31 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 13.96 [1.83; 106.45]
13.96 [1.83 ; 106.45 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 1.88 [0.06; 56.28]
1.88 [0.06 ; 56.28 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 4.36 [1.79; 10.66]
4.36 [1.79 ; 10.66 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.05 [0.00; 0.89]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.20 [0.49; 2.95]
0.34 [0.02 ; 6.97 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 77% 992 low not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.44 [0.71; 2.95]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.08 [0.00; 1.41]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.14 [0.38; 3.45]
1.00 [0.38 ; 2.62 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 46% 2,541 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 649, 2021 0.69 [0.37; 1.29]
JAVELIN Gastric 300, 2018 0.24 [0.01; 5.32]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.03 [0.00; 0.55]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.83 [0.38; 1.83]
0.56 [0.26 ; 1.24 ] CheckMate 649, 2021, JAVELIN Gastric 300, 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 4 41% 2,902 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results JAVELIN Gastric 300, 2018 0.07 [0.00; 1.17]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.18; 21.75]
0.44 [0.06 ; 3.49 ] JAVELIN Gastric 300, 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 36% 1,353 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.14 [0.43; 3.04]
1.14 [0.43 ; 3.04 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Anaemia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.97 [0.54; 1.75]
0.97 [0.54 ; 1.75 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Asthenia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 2.48 [0.54; 11.47]
2.48 [0.54 ; 11.47 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Back pain AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.73 [0.12; 4.41]
0.73 [0.12 ; 4.41 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Constipation AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Decreased appetite AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.54 [0.20; 1.42]
0.54 [0.20 ; 1.42 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Diarrhoea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.22; 17.71]
1.96 [0.22 ; 17.71 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Dyspepsia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Dyspnoea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.96 [0.09; 43.66]
1.96 [0.09 ; 43.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Fatigue AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.29 [0.07; 1.21]
0.29 [0.07 ; 1.21 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Increase AST AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.48 [0.47; 4.67]
1.48 [0.47 ; 4.67 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Increased ALT AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.31 [0.34; 5.00]
1.31 [0.34 ; 5.00 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Nausea AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.24 [0.02; 2.68]
0.24 [0.02 ; 2.68 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pruritus AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Pyrexia AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 1.47 [0.15; 14.22]
1.47 [0.15 ; 14.22 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Rash AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.49 [0.01; 24.66]
0.49 [0.01 ; 24.66 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Vomiting AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.65 [0.14; 2.92]
0.65 [0.14 ; 2.92 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable Weight decreased AE (grade 3-4)detailed results ATTRACTION-2 (Kang), 2017 0.98 [0.03; 29.24]
0.98 [0.03 ; 29.24 ] ATTRACTION-2 (Kang), 2017 1 0% 491 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-04 15:45 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 273,122,271,262,260,219,184,272,123,187,185,186,304
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563